JP2023529499A - 医薬組成物 - Google Patents
医薬組成物 Download PDFInfo
- Publication number
- JP2023529499A JP2023529499A JP2022577091A JP2022577091A JP2023529499A JP 2023529499 A JP2023529499 A JP 2023529499A JP 2022577091 A JP2022577091 A JP 2022577091A JP 2022577091 A JP2022577091 A JP 2022577091A JP 2023529499 A JP2023529499 A JP 2023529499A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- tablets
- tablet
- escitalopram
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 18
- 229960004341 escitalopram Drugs 0.000 claims abstract description 19
- 239000000314 lubricant Substances 0.000 claims abstract description 19
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 claims abstract description 17
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 239000011247 coating layer Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000007884 disintegrant Substances 0.000 claims description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 3
- 229960000913 crospovidone Drugs 0.000 claims description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 3
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 abstract description 16
- 238000004806 packaging method and process Methods 0.000 abstract description 10
- 239000004480 active ingredient Substances 0.000 abstract description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- 239000003814 drug Substances 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- 229920003023 plastic Polymers 0.000 description 9
- 239000004033 plastic Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 7
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 7
- 239000012535 impurity Substances 0.000 description 6
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 5
- 229960001653 citalopram Drugs 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- -1 calcium phosphate Chemical class 0.000 description 3
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- LJPQJFHBFOOIHE-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3-hydroxy-3h-2-benzofuran-5-carbonitrile Chemical compound O1C(O)C2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 LJPQJFHBFOOIHE-UHFFFAOYSA-N 0.000 description 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229940049654 glyceryl behenate Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- ASGSMDPSNUXWMB-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3-oxo-2-benzofuran-5-carbonitrile Chemical compound O1C(=O)C2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 ASGSMDPSNUXWMB-UHFFFAOYSA-N 0.000 description 1
- WVTNHLAXBFGVJR-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile oxide Chemical compound O1CC2=CC(C#[N+][O-])=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WVTNHLAXBFGVJR-UHFFFAOYSA-N 0.000 description 1
- LYYWQJNKWCANAC-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carboxamide Chemical compound O1CC2=CC(C(N)=O)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 LYYWQJNKWCANAC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940041201 escitalopram 10 mg Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
1-(3-ジメチルアミノプロピル)-1-(4-フルオロフェニル)-1,3-ジヒドロイソベンゾフラン-5-カルボキサミド);
1-(3-ジメチルアミノプロピル)-1-(4-フルオロフェニル)-3-ヒドロキシ-1,3-ジヒドロイソベンゾフラン-5-カルボニトリル;3-ヒドロキシシタロプラム;
(3-(3-ジメチルアミノプロピル)-3-(4-フルオロフェニル)-6-シアノ-1(3H)-イソベンゾフラノン;
1-(3-ジメチルアミノプロピル)-1-(4-フルオロフェニル)-1,3-ジヒドロイソベンゾフラン-5-カルボニトリル-N-オキシド
下記の表2の造成に従い、滑沢剤を変えて、それぞれの錠剤を製造した。
上記した比較例1乃至6に従って製造された錠剤を、それぞれPTPで包装し、それぞれの錠剤がPTP包装されたまま、韓国食品医薬品安全処告示「医薬品等の安定性試験基準」による加速試験条件(すなわち、温度40±2℃、相対湿度75±5%)で生成される類縁物質を分析した(それぞれの試験における試験錠剤数n=3)。
下記の表9の造成に従って、本発明で製造される錠剤(実施例)と、対照群として用いられる錠剤(比較例)とをそれぞれ製造した。
核錠の製造過程において、滑沢剤としてベヘン酸グリセリル及びステアリン酸を用いた比較例8は、滑沢力が不足であり、打錠時、下ポンチに粉末がつくスティッキング現象が発生した。したがって、打錠性の側面において、上記した比較例8の造成は適合していないことが確認された。
上記した実施例1と2及び比較例7乃至9に従って製造された錠剤を、それぞれPTPで包装し、それぞれの錠剤がPTP包装されたまま、韓国食品医薬品安全処告示「医薬品等の安定性試験基準」及びICHガイドラインによる苛酷試験条件(すなわち、温度60±2℃、相対湿度80±5%)で生成される類縁物質を分析した(それぞれの試験における試験錠剤数n=3)。
プラスチック瓶に包装されている既存のエスシタロプラム10mgの市販製品のうち4種の製品(下記の表16の対照薬A乃至D)を選択し、プラスチック瓶を開封するやいなや、一部の錠剤を得て、直ちにPTP包装した後、PTP包装されたまま、それぞれの錠剤に対して苛酷試験を行い(温度60±2℃、相対湿度80±5%)、生成される不純物Cの量を分析し、その結果を上記した実施例1の試験結果と比較した(それぞれの試験における試験錠剤数n=3)。
対照薬A:軽質無水ケイ酸及びステアリン酸マグネシウム;
対照薬B:タルク及びステアリン酸マグネシウム
対照薬C:ステアリン酸マグネシウム
対照薬D:ステアリン酸マグネシウム
Claims (7)
- エスシタロプラムまたはその薬剤学的に許容される塩を含有する薬剤学的組成物であって、
滑沢剤として軽質無水ケイ酸または硬化油のうち少なくとも1種を含む薬剤学的組成物。 - 滑沢剤として軽質無水ケイ酸及び硬化油を含む請求項1に記載の薬剤学的組成物。
- 錠剤剤形である請求項1または請求項2に記載の薬剤学的組成物。
- 希釈剤及び崩壊剤をさらに含む請求項3に記載の薬剤学的組成物。
- 希釈剤としてケイ化微結晶セルロースを含む請求項4に記載の薬剤学的組成物。
- 崩壊剤としてクロスポビドンを含む請求項4に記載の薬剤学的組成物。
- 前記錠剤剤形は、コーティング層でコートされている請求項3に記載の薬剤学的組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200072656A KR102441089B1 (ko) | 2020-06-15 | 2020-06-15 | 의약 조성물 |
KR10-2020-0072656 | 2020-06-15 | ||
PCT/KR2021/007518 WO2021256844A1 (ko) | 2020-06-15 | 2021-06-15 | 의약 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2023529499A true JP2023529499A (ja) | 2023-07-10 |
Family
ID=79175960
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022577091A Pending JP2023529499A (ja) | 2020-06-15 | 2021-06-15 | 医薬組成物 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP2023529499A (ja) |
KR (1) | KR102441089B1 (ja) |
WO (1) | WO2021256844A1 (ja) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8814057D0 (en) | 1988-06-14 | 1988-07-20 | Lundbeck & Co As H | New enantiomers & their isolation |
WO2006123243A2 (en) * | 2005-05-20 | 2006-11-23 | Aurobindo Pharma Limited | Pharmaceutical dosage forms comprising escitalopram in form of granules |
JP5153629B2 (ja) | 2005-08-02 | 2013-02-27 | ルピン・リミテッド | 選択的セロトニン再取り込み阻害剤の新規の制御放出組成物 |
EP2211836A2 (en) | 2007-10-10 | 2010-08-04 | Rubicon Research Private Limited | Taste-masked orally disintegrating tablets of memantine hydrochloride |
EP2291177A2 (en) | 2008-05-05 | 2011-03-09 | Farmaprojects, S.A. | Stable pharmaceutical compositions and their processes for preparation suitable for industrial scale |
WO2014131825A1 (en) | 2013-03-01 | 2014-09-04 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical formulations comprising quetiapine and escitalopram |
-
2020
- 2020-06-15 KR KR1020200072656A patent/KR102441089B1/ko active IP Right Grant
-
2021
- 2021-06-15 JP JP2022577091A patent/JP2023529499A/ja active Pending
- 2021-06-15 WO PCT/KR2021/007518 patent/WO2021256844A1/ko active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2021256844A1 (ko) | 2021-12-23 |
KR102441089B1 (ko) | 2022-09-07 |
KR20210155447A (ko) | 2021-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2639473C2 (ru) | Пероральная фармацевтическая композиция | |
US20090042930A1 (en) | Pharmaceutical compositions containing clopidogrel bisulfate | |
HU230877B1 (hu) | Stabil kombinációs gyógyszerkészítmény | |
EP3749286A1 (en) | A pharmaceutical composition comprising metamizole, drotaverine, and caffeine | |
DK159590B (da) | Fremgangsmaade til forhindring af nedbrydning af thieno-pyridinderivater | |
RU2003126177A (ru) | Способ приготовления негигроскопичной композиции вальпроата натрия | |
JP2016104812A (ja) | ロキソプロフェンナトリウム及びトラネキサム酸を含有する固形製剤 | |
JP2023529499A (ja) | 医薬組成物 | |
WO2010027010A1 (ja) | 有効成分が境界を有してなる医薬固形製剤 | |
JP6160263B2 (ja) | ロキソプロフェン含有医薬組成物 | |
SK288240B6 (sk) | Farmaceutický prostriedok na orálne podávanie | |
CA2621134A1 (en) | Pharmaceutical formulation containing an hmg-coa reductase inhibitor and method for the preparation thereof | |
JP2020121950A (ja) | 固形製剤 | |
EP2117534B1 (en) | A pharmaceutical composition with atorvastatin active ingredient | |
CZ20031899A3 (en) | Pharmaceutical tablet comprising paroxetine mesylate | |
JP6114573B2 (ja) | ロキソプロフェンナトリウムと制酸剤を含有する固形製剤 | |
JP2022012138A (ja) | リナグリプチンと光安定化成分を含有する医薬製剤 | |
JP6106359B2 (ja) | ロキソプロフェンナトリウムとビタミンb1を含有する固形製剤 | |
JP5624754B2 (ja) | 内服固形製剤 | |
JP6638947B1 (ja) | 保存安定性に優れたレボセチリジン医薬組成物 | |
JP2010241759A (ja) | 安定性に優れた医薬組成物 | |
KR102254307B1 (ko) | 보관 안정성이 향상된 에페리손 약제학적 조성물 | |
TR201702103A2 (tr) | Vilazodon hi̇droklorürün tablet formlari | |
JP2018030838A (ja) | 固形製剤、錠剤の製造方法およびコーティング錠の製造方法 | |
JP2024007837A (ja) | ラコサミドを含む医薬組成物及びその利用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230213 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231117 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231121 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240214 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240418 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240520 |